Mesoblast

decision path change of plans arrows business decision
Biotech

Mesoblast plots path to market for twice-rejected cell therapy

Mesoblast exited a meeting with the FDA convinced that new potency assay data and a single-arm trial can finally get the candidate to market.
Nick Paul Taylor Sep 21, 2023 6:45am
Executive looking out window

Mesoblast CEO takes 30% pay cut to fund 3rd shot at FDA approval

Aug 31, 2023 5:42am
FDA stop sign

2nd time unlucky for Mesoblast as FDA rejects cell therapy

Aug 4, 2023 8:17am
try again dead end retry restart again second attempt blocked new plan

Mesoblast's 2nd attempt for cell therapy approval moves ahead

Mar 8, 2023 10:35am
graphic of a paper airplane labeled plan A crashing while a rocket labeled plan B takes off

Mesoblast gives cell therapy a 2nd try with FDA—but no new trial

Feb 1, 2023 5:04pm
doctor analyzing medical report network connection on calculator and computer tablet technology - stock photo everythingpos

Mesoblast sees cell therapy survival data as key to resubmission

Nov 23, 2022 9:30am